Antidepressant use and colorectal cancer morbidity and mortality: A dose-response meta analysis
Autor: | Chengbin Li, Chuanxin Zou, Lin Chen, Xun Li |
---|---|
Rok vydání: | 2020 |
Předmět: |
Oncology
medicine.medical_specialty medicine.drug_class Colorectal cancer Serotonin reuptake inhibitor MEDLINE Subgroup analysis Antidepressive Agents Tricyclic 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine medicine Humans 030212 general & internal medicine Serotonin and Noradrenaline Reuptake Inhibitors Serotonin–norepinephrine reuptake inhibitor Depressive Disorder Dose-Response Relationship Drug business.industry General Medicine medicine.disease Confidence interval Antidepressive Agents 030220 oncology & carcinogenesis Meta-analysis Antidepressant business Colorectal Neoplasms |
Zdroj: | Medicine. 99(22) |
ISSN: | 1536-5964 |
Popis: | The risk of colorectal cancer associated to antidepressant use remains unclear. The purpose of this meta-analysis was to investigate the risk of colorectal cancer associated to antidepressant use.Medline, Embase, Web of Science, and Cochrane Database were accessed from the dates of their establishment to October 2018, to collect study of antidepressant use and colorectal cancer morbidity and mortality. Then a meta-analysis was conducted using Stata 12.0 software.A total of 11 publications involving 109,506 participants were included. The meta-analysis showed that antidepressant use was not associated with colorectal cancer morbidity (relevant risk (RR): 0.97; 95% confidence interval (CI): 0.94-1.01) and mortality (RR: 1.08; 95% CI: 0.99-1.17). Subgroup analysis showed selective serotonin reuptake inhibitor (RR: 0.99; 95% CI: 0.96-1.03) or serotonin norepinephrine reuptake inhibitor (RR: 1.04; 95% CI: 0.86-1.26) were not associated with colorectal cancer risk; however, TCA was associated with colorectal cancer risk decrement (RR: 0.92; 95% CI: 0.87-0.98). Furthermore, the results also showed that antidepressant use was not associated with colorectal cancer risk in Europe and North America (RR: 0.97; 95% CI: 0.92-1.02) and Asia (RR: 1.00; 95% CI: 0.95-1.26). Additionally, a dose-response showed per 1 year of duration of antidepressant use incremental increase was not associated with colorectal cancer risk (RR: 0.96; 95% CI: 0.87-1.09).Evidence suggests that antidepressant use was not associated with colorectal cancer morbidity and mortality. The cumulative duration of antidepressant use did not utilized played critical roles. |
Databáze: | OpenAIRE |
Externí odkaz: |